Dante Labs Announces Expansion of its Finance Team with the Appointment of Andre Nel as Chief Financial Officer, Dalila Rahmani as Chief Accounting Officer, Laura D’Angelo as VP Investor Relations and Omar Elbakshish as Senior Director
CAMBRIDGE, United Kingdom, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Dante Labs, a global leader in genomics and precision medicine, today announced the appointments of Andre Nel, Dalila Rahmani, Laura D’Angelo and Omar Elbakshish to the company’s management team, expanding its global leadership to help scale the growing business.
“We are thrilled to welcome Andre, Dalila, Laura and Omar to the expanding leadership team here at Dante,” said Andrea Riposati, CEO of Dante Labs. “As we work to deliver a more human approach to healthcare, it is our shared vision of the future and growing importance genomics is playing in healthcare that will help to meet the unmet needs of our customers from whole genome sequencing to drug discovery and development to COVID testing.”
These leaders will join Dante’s finance team to help scale the business as we work to deliver a global brand of tests and services resulting in better outcomes for people around the world.
Leading the team, Andre Nel joins Dante Labs as Chief Financial Officer. Andre brings more than 20 years of experience providing high-value strategic and operational financial support for global multibillion-dollar organizations such as Pfizer and Illumina. Most recently, Andre was the Vice President of Finance at Illumina (NASDAQ: ILMN) in San Diego.
Dalila joins Dante Labs as the Chief Accounting Officer. Dalila previously worked with Andre at Illumina as the head of Controllership and Shared Services for the EMEA region. Dalila has most recently led the Illumina Commercial Finance team, specializing in financial forecasting, budgeting, business partnering and management. Prior to joining Illumina she started her career as an auditor with Ernst & Young. Dalila has a demonstrated history working in the biotechnology industry and a master’s degree focused on Accounting and Finance. Her work in the industry will benefit us greatly in our more personalized approach to medicine and healthcare.
Laura D’Angelo joins Dante Labs as Vice President of Investor Relations. Most recently, Laura was the Head of Investor Relations at Invitae (NYSE: NVTA), specializing in external communication targeting analysts, investors and financial media as well as clinician and patient customers. With a career rooted in communications, Laura brings a unique perspective to Dante’s finance team as we turn sequencing data into life-saving answers for the people we serve.
Omar Elbakshish joins Dante Labs as Senior Director of Business Finance. Skilled in financial modeling, forecasting and business partnering, Omar also joins Dante from Illumina. With a demonstrated history working in finance roles in the biotechnology industry throughout his career, Omar will help Dante to deploy genomic applications that have real impact on people’s lives.
“I’m so pleased to be leading this passionate and talented finance team here at Dante Labs to help accelerate genomics on a global scale to improve healthcare outcomes,” said Andre Nel, Chief Financial Officer of Dante Labs. “Having worked previously with Dalila and Omar and now collaborating with Laura, I’m confident we have the right team of professionals to achieve our mission and demonstrate how essential genomics is to a holistic and human approach to healthcare around the world.”
About Dante Labs
Dante Labs is a global genomic data company building and commercializing a new class of transformative health and longevity applications based on whole genome sequencing and AI. Our assets include one of the largest private genome databases with research consent, a proprietary software platform designed to unleash the power of genomic data at scale and proprietary processes which enable an industrial approach to genomic sequencing.
Headquartered in Cambridge, United Kingdom, with a research laboratory in Wolverhampton, Dante Labs supported the UK Government’s urgent requirement to scale-up a high-capacity, highly automated testing solution for Covid-19, including infected patients as well as those with antibodies. Dante Labs was able to deliver by leveraging existing technology that had been developed for whole genome sequencing.To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
After safety review The Connection study is now again open to recruit the smallest infants.22.9.2021 22:30:00 CEST | Press release
After safety review The Connection study is now again open to recruit the smallest infants. Following the completion of the DMC (Data Monitoring Committee) safety review, IBT is pleased to announce the continuation of the recruitment of patients between 500 - 1000g (Strata A and B) in the Connection study. “Given the vulnerability of the Stratum A population, infants with a birth weight less than 750 gram, we have agreed with the FDA to carefully monitor the safety of these infants. Therefore, the independent DMC has completed an additional safety review, and there are no objections to continue the study. We expect recruitment to increase as we now again recruit in two strata. ” Says Staffan Strömberg, Chief Executive Officer of IBT. About Infant Bacterial Therapeutics AB Infant Bacterial Therapeutics AB (“IBT”) is a public company domiciled in Stockholm. The company’s Class B shares are listed on Nasdaq Stockholm, Mid-cap (IBT B). Infant Bacterial Therapeutics AB (publ) (“IBT”) is a p
Efter säkerhetsgranskning har rekryteringen av de minsta barnen i the Connection study återupptagits.22.9.2021 22:30:00 CEST | Pressemelding
Efter säkerhetsgranskning har rekryteringen av de minsta barnen i the Connection study återupptagits. Efter att säkerhetsgranskningen som utförts av Data Monitoring Committee (DMC) har slutförts kan IBT nu lämna det glädjande beskedet att rekryteringen av spädbarn i båda viktgrupperna, 500–1000 gram (Strata A och B), kan fortsätta. ”Med anledning av att spädbarnen i stratum A, som har en födelsevikt på mindre än 750 gram, är mycket känsliga har vi enats med FDA om att övervaka säkerheten för dessa spädbarn mycket noggrant. Den oberoende DMC har med anledning av detta slutfört en extra säkerhetsgranskning där det inte föreligger några invändningar mot att fortsätta studien. Vi förväntar oss att rekryteringstakten kommer att öka när vi återigen kan rekrytera i två strata. ” säger Staffan Strömberg, VD för IBT. Om Infant Bacterial Therapeutics AB Infant Bacterial Therapeutics AB (”IBT”) är ett publikt bolag med säte i Stockholm. Bolagets aktier av serie B handlas på Nasdaq Stockholm, Mid
Weekly share repurchase program transaction details22.9.2021 19:34:35 CEST | Press release
September 22, 2021 SBM Offshore reports the transaction details related to its EUR150 million (c. US$180 million) share repurchase program for the period September 16, 2021 through September 22, 2021. The repurchases were made under the EUR150 million share repurchase program announced on and effective from August 5, 2021. The objective of the program is to reduce share capital and, in addition, to provide shares for regular management and employee share programs. Information regarding the progress of the share repurchase program and the aggregate of the transactions (calculated on a daily basis) for the period August 5, 2021 through September 22, 2021 can be found in the top half of the table below. Further detailed information regarding both the progress of the share repurchase program and all individual transactions can be accessed via the Investors section of the Company’s website. Share Repurchase Program Overall progress Share Repurchase Program: Total Repurchase Amount EUR 150,0
21Shares Announces Listing of Six Additional Crypto ETPs on Deutsche Boerse XETRA22.9.2021 19:11:35 CEST | Press release
Firm is first and only to give investors access to 10 crypto listings in Germany September 22, 2021 – 21Shares AG (“21Shares”), the world’s largest issuer of cryptocurrency ETPs, today announced the listing of six additional cryptocurrency ETPs for a total of 10 on Deutsche Boerse XETRA, Germany’s top trading venue for exchange traded funds. The new crypto ETPs include Solana ETP (Ticker: 21XL GY), Polkadot ETP (Ticker: PDOT GY), Cardano ETP (Ticker: DADA GY), Stellar Lumens ETP (Ticker: XLME GY), Tezos (Ticker: 21XZ GY), and the Crypto Basket Index ETP (Ticker:21XH GY). Hany Rashwan, Co-Founder and CEO of 21Shares said, “We are pleased to expand crypto investment opportunities in Germany, as one of our key markets, where we are the first and only firm providing such a comprehensive product suite. This development underscores our commitment to helping investors safely access crypto assets, now and in the future.” The six Xetra-listed crypto ETPs emphasize 21Shares’ leadership in crypto
Regarding public information about Klaipeda Prosecutor Office civil claim concerning AB “Klaipedos nafta” shares granted to employees22.9.2021 18:03:11 CEST | Press release
Public sources of information provided that the Klaipeda Prosecutor Office has submitted a civil claim against AB "Klaipedos nafta" (KN) on a ground of protection of public interest. As suggested by the media, a civil claim is concerning shares granted to employees in 2019. KN granted the shares to employees in 2019 according to the Rules for granting shares, which were approved in the general shareholders meeting. Relevant link: https://view.news.eu.nasdaq.com/view?id=b4561c449403dd0740cf7ee2c12302f9d&lang=en KN has not received a civil claim, thus is unable to provide any comments on the issue. Chief Financial Officer Mindaugas Kvekšas, +370 614 82665
Touax: H1 2021 results22.9.2021 17:45:00 CEST | Press release
PRESS RELEASE Paris, 22 September 2021 – 5.45 p.m. YOUR OPERATIONAL LEASING SOLUTION FOR SUSTAINABLE TRANSPORTATION H1 2021 results Restated revenue from activities of €52.5 million, up €1.2 millionResilient business performance with EBITDA of €21.3 million and the Group share of net income amounting to €2.0 millionFavourable outlook with strong investments Touax Group continued to deliver a positive performance while the health crisis caused further disruption. Its results were stable against the same period in 2020, with the exception of sales fees, which declined but were partially offset by sales of owned equipment. The growth in the shipping container leasing business, driven by the shortage of containers, limited asset returns and therefore sales of used containers and sales fees. ANALYSIS OF H1 2021 REVENUE FROM ACTIVITIES The restated presentation of revenue from activities is as follows: Restated Revenue from activities (in € thousand)Q1 2021Q2 2021H1 2021Q1 2020Q2 2020H1 2020
Bolder Surgical announces global launch of the CoolSeal™ Vessel Sealing Platform22.9.2021 16:44:21 CEST | Press release
CoolSeal receives CE mark, Japan PMDA approval; now available in over 20 countries worldwide LOUISVILLE, COLORADO, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Bolder Surgical today announced the global launch of its CoolSeal™ Vessel Sealing platform. CoolSeal has been in use since October 2020 in the U.S., and with the new international regulatory approvals the devices are available in over 20 countries around the world. Bolder Surgical provides surgeons precision electrosurgical instruments to perform minimally invasive surgery safely and effectively in pediatric and adult procedures including general, gynecological and bariatric surgical applications. The CoolSeal Vessel Sealing suite includes the 3 mm Mini (formerly JustRight Sealer) and the 5 mm Trinity Sealer/Divider/Dissector. Both devices are powered with the gold-standard efficacy of advanced bipolar RF vessel sealing technology. “Having successfully used the 3 mm vessel sealer for many cases in pediatric surgery, the Trinity 5 mm devic